Titre-specific positive predictive value of nuclear patterns (University Hospitals Leuven)
| 1/80 (PPV, (n)) | 1/160 (PPV, (n)) | 1/320 (PPV, (n)) | 1/640 (PPV, (n)) | ≥1/1280 (PPV, (n)) | SSA* (PPV, n) | ||||||||||||||||
| Homogeneous† | Speckled | Nucleolar* | Centromere | Homogeneous† | Speckled | Nucleolar* | Centromere | Homogeneous‡ | Speckled | Nucleolar* | Centromere | Homogeneous‡ | Speckled | Nucleolar* | Centromere | Homogeneous‡ | Speckled | Nucleolar* | Centromere | ||
| AASRDs | 0.03 (8) | 0.04 (5) | 0.02 (1) | – | 0.06 (14) | 0.13 (10) | 0.19 (8) | 0.29 (2) | 0.11 (8) | 0.39 (12) | 0.31 (8) | 0.42 (5) | 0.32 (9) | 0.32 (7) | – | 0.77 (17) | 0.40 (12) | 0.71 (20) | 0.61 (11) | 0.82 (14) | 0.47 (53) |
| SLE | 0.01 (4) | 0.01 (2) | 0.02 (1) | – | 0.04 (10) | 0.06 (5) | 0.07 (3) | – | 0.09 (6) | 0.10 (3) | 0.08 (2) | 0.08 (1) | 0.21 (6) | 0.14 (3) | – | – | 0.23 (7) | 0.29 (8) | – | – | 0.20 (22) |
| SjS | 0.01 (3) | 0.01 (1) | – | – | – | – | – | – | – | 0.06 (2) | – | 0.08 (1) | 0.04 (1) | – | – | – | – | – | – | 0.06 (1) | 0.24 (27) |
| SSc | 0.00 (1) | 0.01 (1) | – | – | – | 0.03 (2) | 0.12 (5) | 0.29 (2) | 0.03 (2) | 0.06 (2) | 0.15 (4) | 0.25 (3) | 0.04 (1) | 0.09 (2) | – | 0.77 (17) | 0.10 (3) | 0.04 (1) | 0.56 (10) | 0.76 (13) | 0.01 (1) |
| IIM | – | 0.01 (1) | – | – | 0.00 (1) | 0.04 (3) | – | – | – | 0.10 (3) | 0.08 (2) | – | – | 0.09 (2) | – | – | 0.07 (2) | 0.07 (2) | 0.06 (1) | – | 0.02 (2) |
| MCTD | – | – | – | – | 0.00 (1) | – | – | – | – | 0.03 (1) | – | – | – | – | – | – | – | 0.32 (9) | – | – | – |
| UCTD | – | – | – | – | 0.01 (2) | – | – | – | 0.01 (1) | 0.03 (1) | – | – | 0.03 (1) | – | – | – | – | – | – | – | 0.01 (1) |
| AIH | 0.00 (1) | 0.01 (1) | 0.02 (1) | – | 0.00 (1) | – | 0.02 (1) | – | 0.02 (2) | – | 0.04 (1) | – | – | – | 0.13 (1) | 0.13 (1) | 0.07 (2) | – | – | – | 0.02 (2) |
| CLE | 0.00 (1) | 0.01 (2) | – | – | 0.01 (2) | – | – | – | 0.01 (1) | – | – | – | – | – | – | – | – | – | – | – | 0.08 (9) |
| JIA | 0.02 (5) | 0.01 (2) | – | – | 0.03 (8) | – | – | – | 0.03 (3) | 0.03 (1) | – | – | 0.04 (1) | – | – | – | – | 0.04 (1) | – | – | 0.01 (1) |
| Other (n) | 255 | 124 | 56 | 1 | 218 | 68 | 34 | 5 | 56 | 18 | 17 | 7 | 18 | 15 | 7 | 5 | 16 | 7 | 7 | 3 | 45 |
| Total (n) | 270 | 134 | 58 | 1 | 243 | 78 | 43 | 7 | 70 | 31 | 26 | 12 | 28 | 22 | 8 | 22 | 30 | 28 | 18 | 17 | 110 |
*Combinations with other nuclear patterns included.
†Including possible anti-DFS70-positive samples.
‡Anti-DFS70-positive (monospecific) samples excluded, only samples with monospecific homogeneous pattern with titre ≥1:320, negative dsDNA Farr assay and negative CTD Screen were tested for anti-DFS70 antibodies,.
§No positive samples.
.AASRD, ANA-associated systemic rheumatic disease;AIH, autoimmune hepatitis; CLE, cutaneous lupus erythematosus; IIM, idiopathic inflammatory myopathy; JIA, juvenile idiopathic arthritis; MCTD, mixed connective tissue disease; PPV, positive predictive value; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease.